The estimated Net Worth of Elizabeth Garrett Ingram is at least $46.4 Thousand dollars as of 12 September 2019. Elizabeth Ingram owns over 16,000 units of Avenue Therapeutics Inc stock worth over $46,400 and over the last 6 years Elizabeth sold ATXI stock worth over $0.
Elizabeth has made over 2 trades of the Avenue Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Elizabeth bought 16,000 units of ATXI stock worth $100,320 on 12 September 2019.
The largest trade Elizabeth's ever made was buying 16,000 units of Avenue Therapeutics Inc stock on 12 September 2019 worth over $100,320. On average, Elizabeth trades about 3,500 units every 37 days since 2018. As of 12 September 2019 Elizabeth still owns at least 16,000 units of Avenue Therapeutics Inc stock.
You can see the complete history of Elizabeth Ingram stock trades at the bottom of the page.
Elizabeth's mailing address filed with the SEC is 30930 Russell Ranch Rd, Westlake Village, CA 91362, USA.
Over the last 7 years, insiders at Avenue Therapeutics Inc have traded over $3,169,091 worth of Avenue Therapeutics Inc stock and bought 867,969 units worth $1,169,423 . The most active insiders traders include Lindsay A Md Rosenwald, Michael S Weiss, and Robert L Davidow. On average, Avenue Therapeutics Inc executives and independent directors trade stock every 87 days with the average trade being worth of $210,758. The most recent stock trade was executed by Robert L Davidow on 11 December 2023, trading 617,000 units of ATXI stock currently worth $86,380.
avenue therapeutics, inc. (nasdaq: atxi), a fortress biotech (nasdaq: fbio) company, is a specialty pharmaceutical company focused on the development and commercialization of intravenous (iv) tramadol for the management of moderate to moderately severe postoperative pain. iv tramadol may fill a gap in the acute pain market between iv acetaminophen/nsaids and iv conventional narcotics. avenue is currently evaluating iv tramadol in a pivotal phase 3 program for the management of postoperative pain.
Avenue Therapeutics Inc executives and other stock owners filed with the SEC include: